Lipid Metabolic Status in Thyroid Carcinoma (LITCA)
The continuous increase of the incidence of the thyroid cancer in the last years has taken this neoplasia among the first 4 frequent cancers in the cancer registry of the Institute of Oncology "Prof.Ion Chiricuţă" from Cluj-Napoca (IOCN), with a total number of over 470 new cases per year, added to the other 3700 cases already being in the evidence of the Institute.
The radical treatment brings for a long term a compensated chronic drug induces mYxoedema with it's important side effects. Among these one can find the dislipidemia and the change of the high sensitive C reactive protein (hsCRP) serological value. In the last years, many epidemiological studies have confirmed the fact that the patients with a high serological value of the hsCRP present a higher risk for the coronary disease and heart attack.
Prospective studies developed in european countries and in USA have provided results that are related to the predictive value of the hsCRP determinations over the cardiovascular risk. Thus, hsCRP is an indirect risk factor for the coronary disease. The risk for cardiovascular disease is 2 to 7 times higher at the people with a high level of hsCRP comparing to ones with low levels; the increase of the hsCRP serological value can be determined several years before the clinical debut of the coronary disease.
The screening for this population group with a high risk can introduce in use the prevention of the cardiac pathology and change the approach to the monitoring of the patients with thyroid cancer. A selection protocol will be elaborated for the patients that will withdraw the hormone treatment by using recombinant thyroid stimulating hormone (TSH) or will have personalised monitoring algorithm, with a shortening of the hormone treatment withdrawal.
Risk Reduction Behavior
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||"Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution"|
- hsCRP an inflammatory biomarker for cardiovascular risk [ Time Frame: May 2012 ] [ Designated as safety issue: No ]hsCRP in thyroid hormone withdrwal for patients with thyroid carcinoma radically treated
- hsCRP may increase in repeated thyroid hormone withdrawal [ Time Frame: May 2012 ] [ Designated as safety issue: No ]
- hsCRP related to thyroid hormone withdrawal in patients with thyroid carcinoma radically treated [ Time Frame: May 2012 ] [ Designated as safety issue: No ]
|Study Start Date:||February 2011|
|Study Completion Date:||May 2012|
|Primary Completion Date:||February 2012 (Final data collection date for primary outcome measure)|
|Thyroid cancer, lipids, LT4 withdrawal|
|Thyroid cancer, Lipids, LT4 substitution|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01487057
|Institute of Oncology "Prof.dr.I.Chiricuta"|
|Cluj-Napoca, Cluj, Romania, 400015|
|Study Director:||Alexandru Irimie, PhD||IOCN|